title: Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia.
abstract: Parathyroidectomy (PTx) is indicated in hemodialysis (HD) patients who have severe osteitis fibrosa unresponsive to vitamin D therapy or in whom the latter treatment is contraindicated. Immediately after PTx, plasma immunoreactive parathyroid hormone, calcium and phosphorus concentrations decline abruptly. However, little is known in such patients about the short-term effects of PTx on plasma alkaline phosphatase (AP) activity and plasma aluminum (Al) levels. The present, preliminary study was performed to determine such parameters in 37 HD patients, and to correlate them with data of bone histology. Mean plasma AP activity started to increase after PTx from day 4 onwards. Thus, AP values significantly higher than pre-PTx values were observed at day 7 and 14 (415 +/- 54 vs. 619 +/- 77 and 749 +/- 83 IU/liter, means +/- SEM; N = 37; P less than 0.05 and 0.001, respectively). This increase, in the absence of changes in liver function, was mainly due to the bone-specific iso-AP. Moreover, the degree of increase in plasma AP activity was higher in the subgroup with negative (group I, 21 patients) than in that with positive bone Al staining (group II, 16 patients). However, plasma osteocalcin (BGP) did not change after PTx (N = 8). Basal plasma Al levels were significantly higher in group II both before and two weeks after surgery.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Département de Néphrologic, INSERM U90, CNRS UA 583, Hôpital Necker-Enfants Malades, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Ureña
authors.forename: C
authors.initials: C
authors.lastname: Basile
authors.forename: G
authors.initials: G
authors.lastname: Grateau
authors.forename: B
authors.initials: B
authors.lastname: Lacour
authors.forename: A
authors.initials: A
authors.lastname: Vassault
authors.forename: A
authors.initials: A
authors.lastname: Bourdeau
authors.forename: R
authors.initials: R
authors.lastname: Bourdon
authors.forename: C
authors.initials: C
authors.lastname: Dubost
authors.forename: J
authors.initials: J
authors.lastname: Zingraff
authors.forename: T
authors.initials: T
authors.lastname: Drüeke
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood; D000535:Aluminum / Q000097:blood; D001842:Bone and Bones / Q000473:pathology; D002112:Calcifediol / Q000097:blood; D002118:Calcium / Q000097:blood; D002908:Chronic Disease; D015331:Cohort Studies; D003676:Deferoxamine; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000601:surgery*; D015675:Osteocalcin / Q000097:blood; D010280:Parathyroid Glands / Q000601:surgery*; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects; D013997:Time Factors; D014511:Uremia / Q000097:blood* / Q000150:complications; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D010281:Parathyroid Hormone; D015675:Osteocalcin; D010758:Phosphorus; D000535:Aluminum; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D003676:Deferoxamine; D002112:Calcifediol; D002118:Calcium